Compare AHG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHG | NVAX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2017 | 1996 |
| Metric | AHG | NVAX |
|---|---|---|
| Price | $2.00 | $8.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 14.4K | ★ 3.1M |
| Earning Date | 08-14-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.27 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $1.08 | $5.80 |
| 52 Week High | $2.50 | $11.85 |
| Indicator | AHG | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 40.20 |
| Support Level | $1.57 | $8.01 |
| Resistance Level | $2.46 | $8.45 |
| Average True Range (ATR) | 0.18 | 0.35 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 22.03 | 29.30 |
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.